Helsinn’s extensive network of partners who commercialize the group’s products around the world has been built and constantly expanded over several decades. It represents our strong commitment to bringing to as many patients as possible our comprehensive portfolio of medicines and therapies, aiming at helping to improve the lives of patients.
Helsinn has built a comprehensive portfolio of market-leading products, such as Aloxi®, the market-leading treatment for chemotherapy induced nausea and vomiting (CINV) and the next generation Akynzeo®, the first approved fixed combination oral agent that targets two critical signalling pathways associated with CINV by combining netupitant, an NK1 receptor antagonist, and palonosetron, a 5-HT3 receptor antagonist, in a single capsule for the prevention of CINV. Akynzeo® has now been approved and is marketed in the US, Europe, Australia, Israel and more recently it has been included as a treatment option in the ASCO, NCCN, and ESMO/MASCC anitemesis guidelines.
Our out-licensing partners share our values and ambition to improve the everyday lives of patients and benefit from a constant and tailored support.We would be happy to further extend our network for selected products and territories, contact us to learn more.